KPTI - Karyopharm Therapeutics Inc

KPTI - Karyopharm Therapeutics Inc

https://www.karyopharm.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Karyopharm Therapeutics ( KPTI ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.04

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Karyopharm Therapeutics ( KPTI ) Is a Great 'Buy the Bottom' Stock Now

Zacks Commentary • 3 months, 2 weeks ago • score: 0.43

Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Karyopharm Therapeutics ( NASDAQ:KPTI )

Benzinga • 4 months ago • score: 0.16

Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday. The company posted quarterly losses of $2.77 per share which beat the analyst consensus estimate of losses of $4.16 per share.

Karyopharm Therapeutics ( KPTI ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months ago • score: -0.07

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 34.20% and 16.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.

52W High

$16.95

52W Low

$3.51

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.35

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.85

EV/Revenue (<3 favorable)

1.43

P/S (TTM) (<3 favorable)

0.42

P/B (<3 favorable)

12.05

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

6.29%

Institutions (25–75% balanced)

51.13%

Shares Outstanding

8,671,300

Float

7,918,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

137,269,000

Gross Profit (TTM)

138,676,000

EPS (TTM)

-14.84

Profit Margin (>10% good)

-0.90%

Operating Margin (TTM) (higher better)

-0.64%

ROE (TTM) (>15% strong)

-8.91%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.11

Momentum

Bearish momentum

Value

0.4209

Previous

0.4651

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025